Karla I. AriasDr. sc. nat.
Overview
Karla I. Arias, D.Sc., focuses her practice on patent and trade secret litigation and prosecuting patents for chemical and pharmaceutical clients.
Before joining Crowell & Moring, Karla was a postdoctoral fellow at Carnegie Mellon University, where her research focused on investigating the degradation of endocrine-disrupting contaminants in water and the formation and reactivity of iron complexes.
Karla received her doctorate in organic chemistry at the University of Zurich, where her research focused on the synthesis of supramolecular architectures and the study of fluorescent and phosphorescent properties of supramolecular building blocks.
Career & Education
- University of California, San Diego, B.S., chemistry, 2004
- University of Zurich, M.Sc., chemistry, 2006
- University of Zurich, Dr. sc. nat., organic chemistry, 2011
- George Mason University, J.D., 2018
- District of Columbia
- U.S. Patent and Trademark Office (USPTO)
Professional Activities and Memberships
- HNBA/Microsoft Intellectual Property Law Institute (IPLI) Fellow
Karla's Insights
Client Alert | 4 min read | 03.24.25
USPTO Finds Claims of Two of Moderna’s mRNA Patents Unpatentable: What’s Next in the Vaccine Wars?
On Wednesday, March 5, 2025, the United States Patent Trial and Appeal Board (“PTAB”) handed down the latest decision in the COVID vaccine proceedings between Pfizer Inc. (“Pfizer”) and BioNTech SE (“BioNTech”) and ModernaTX, Inc. (“Moderna”). The PTAB found all challenged claims unpatentable in two patents held by Moderna related to Moderna’s COVID-19 vaccine technology: U.S. Patent Nos. 10,702,600 (the “’600 patent”) and 10,933,127 (the “’127 patent”), both entitled “Betacoronavirus mRNA Vaccine.”
Client Alert | 4 min read | 03.11.25
Client Alert | 3 min read | 02.21.24
Federal Circuit Hints at the Scope of Government’s License Rights
Representative Matters
- Waters Tech., Inc. & Waters Corp., Inc. v. Agilent Techs., Inc., No. 18-1450-MN (D. Del.)– Representing Agilent in a patent infringement suit on N-glycan labeling reagent.
- Secured a significant victory (a preliminary injunction against patent infringement through trial) on behalf of Lonza Walkersville, Inc. against Israel-based Adva Biotechnology Ltd. in a case involving point-of-care cell-therapy technology.
Karla's Insights
Client Alert | 4 min read | 03.24.25
USPTO Finds Claims of Two of Moderna’s mRNA Patents Unpatentable: What’s Next in the Vaccine Wars?
On Wednesday, March 5, 2025, the United States Patent Trial and Appeal Board (“PTAB”) handed down the latest decision in the COVID vaccine proceedings between Pfizer Inc. (“Pfizer”) and BioNTech SE (“BioNTech”) and ModernaTX, Inc. (“Moderna”). The PTAB found all challenged claims unpatentable in two patents held by Moderna related to Moderna’s COVID-19 vaccine technology: U.S. Patent Nos. 10,702,600 (the “’600 patent”) and 10,933,127 (the “’127 patent”), both entitled “Betacoronavirus mRNA Vaccine.”
Client Alert | 4 min read | 03.11.25
Client Alert | 3 min read | 02.21.24
Federal Circuit Hints at the Scope of Government’s License Rights
Insights
Removal of Ecotoxicity of 17a-ethinylestradiol using TAML/Peroxide Water Treatment
|01.01.15
Scientific Reports, 5, 10511-10520
"Linear Bilateral Extended 2,2’:6’,2”-Terpyridine Ligands, Their Coordination Complexes, and Heterometallic Supramolecular Networks," Chemical Science, 5, 4317-4327
|04.01.14
Synthesis of a D3-Symmetric 'Trefoil' Knotted Cyclophane
|04.01.11
Chemical Communications, 47, 9588-9590
Synthesis of Arylbromides from Arenes and N-bromosuccinimide (NBS) in Acetonitrile – A Convenient Method for Aromatic Bromination
|04.01.09
Canadian Journal of Chemistry, 87, 440-447
Ninth Circuit’s Decision Sheds Light on Important Considerations in Granting Injunctive Relief
|02.20.24
Crowell & Moring’s Trade Secrets Trends
Karla's Insights
Client Alert | 4 min read | 03.24.25
USPTO Finds Claims of Two of Moderna’s mRNA Patents Unpatentable: What’s Next in the Vaccine Wars?
On Wednesday, March 5, 2025, the United States Patent Trial and Appeal Board (“PTAB”) handed down the latest decision in the COVID vaccine proceedings between Pfizer Inc. (“Pfizer”) and BioNTech SE (“BioNTech”) and ModernaTX, Inc. (“Moderna”). The PTAB found all challenged claims unpatentable in two patents held by Moderna related to Moderna’s COVID-19 vaccine technology: U.S. Patent Nos. 10,702,600 (the “’600 patent”) and 10,933,127 (the “’127 patent”), both entitled “Betacoronavirus mRNA Vaccine.”
Client Alert | 4 min read | 03.11.25
Client Alert | 3 min read | 02.21.24
Federal Circuit Hints at the Scope of Government’s License Rights
